Characterization of the cytokine pattern of porcine bone marrow-derived cells treated with 1α,25(OH)2D3

Journal of Veterinary Medicine Series A: Physiology Pathology Clinical Medicine

Volumn 52, Issue 8, 2005, Pages 382-387

  Sipos, W ^a   Duvigneau, J C ^a   Schmoll, F ^a   Exel, B ^a   Hofbauer, G ^a,b   Baravalle, G ^a,b   Hartl, R T ^a   Dobretsberger, M ^a   Pietschmann, P ^b  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CYTOKINE; DIHYDROXY VITAMIN D3; DIHYDROXY-VITAMIN D3; DRUG DERIVATIVE; MEMBRANE PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; VITAMIN D;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE MARROW CELL; CELL CULTURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; LEUKOCYTE; MALE; METABOLISM; OSTEOCLAST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE;

ANIMALS; BONE MARROW CELLS; CARRIER PROTEINS; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; LEUKOCYTES; MALE; MEMBRANE GLYCOPROTEINS; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SWINE; VITAMIN D;

MURINAE; SUIDAE;

EID: 27844607300     PISSN: 0931184X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0442.2005.00755.x     Document Type: Article

References (32)

1. Bendixen, A. C., N. K. Shevde, K. M. Dienger, T. M. Willson, C. D. Funk, and J. W. Pike, 2001: IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor γ 1. Proc. Natl. Acad. Sci. U.S.A. 98, 2443-2448.
2. Bordin, L., G. Priante, E. Musacchio, S. Giunco, E. Tibaldi, G. Clari, and B. Baggio, 2003: Arachidonic acid-induced IL-6 expression is mediated by PKC α activation in osteoblastic cells. Biochemistry 42, 4485-4491.
3. Eghbali-Fatourechi, G., S. Khosla, A. Sanyal, W. J. Boyle, D. L. Lacey, and B. L. Riggs, 2003: Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111, 1221-1230.
4. Fox, S. W., S. J. Haque, A. C. Lovibond, and T. J. Chambers, 2003: The possible role of TGF-β-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J. Immunol. 170, 3679-3687.
5. Gwaltney, S. M., R. J. S. Galvin, K. B. Register, R. B. Rimler, and M. R. Ackermann, 1997: Effects of Pasteurella multocida toxin on porcine bone marrow cell differentiation into osteoclasts and osteoblasts. Vet. Pathol. 34, 421-430.
6. Horwood, N. J., J. Elliott, T. J. Martin, and M. T. Gillespie, 2001: IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. 166, 4915-4921.
7. Huang, W., R. J. O'Keefe, and E. M. Schwarz, 2003: Exposure to receptor-activator of NFκB ligand renders pre-osteoclasts resistant to IFN-γ by inducing terminal differentiation. Arthritis Res. Ther. 5, 49-59.
8. Khapli, S. M., L. S. Mangashetti, S. D. Yogesha, and M. R. Wani, 2003: IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NFκB ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. J. Immunol. 171, 142-151.
9. Kong, Y.-Y., U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li, R. Elliott, S. McCabe, T. Wong, G. Campagnuolo, E. Moran, E. R. Bogoch, G. Van, L. T. Nguyen, P. S. Ohashi, D. L. Lacey, E. Fish, W. J. Boyle, and J. M. Penninger, 1999: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309.
10. Kudo, O., Y. Fujikawa, I. Itonaga, A. Sabokbar, T. Torisu, and N. A. Athanasou, 2002: Proinflammatory cytokine (TNF/IL-1) induction of human osteoclast formation. J. Pathol. 198, 220-227.
11. Lacey, D. L., E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Cappaerlli, A. Eli, Y. X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Seanldi, J. Guo, J. Delaney, and W. J. Boyle, 1998: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
12. Lee, S. K., and J. A. Lorenzo, 1999: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140, 3552-3561.
13. 3 in osteoclat formation. Biochem. Biophys. Res. Commun. 291, 987-994.
14. Nakashima, T., T. Wada, and J. M. Penninger, 2003: RANKL and RANK as novel therapeutic targets for arthritis. Curr. Opin. Rheumatol. 15, 280-287.
15. Nanes, M. S., 2003: Tumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology. Gene 4, 1-15.
16. Palmqvist, P., E. Persson, H. H. Conaway, and U. H. Lerner, 2002: IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NFκB ligand, osteoprotegerin, and receptor activator of NFκB in mouse calvariae. J. Immunol. 169, 3353-3362.
17. 3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Ped. Res. 52, 12-18.
18. Quinn, J. M., K. Itoh, N. Udagawa, K. Hausler, H. Yasuda, N. Shima, A. Mizuno, K. Higashio, N. Takahashi, T. Suda, T. J. Martin, and M. T. Gillespie, 2001: Transforming growth factor β affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16, 1787-1794.
19. Romas, E., M. T. Gillespie, and T. J. Martin, 2002: Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 30, 340-346.
20. Roodman, G. D., 1999: Cell biology of the osteoclast. Exp. Hematol. 27, 1229-1241.
21. Rude, R. K., H. E. Gruber, L. Wie, A. Frausto, and B. G. Mills, 2003: Magnesium deficiency: effect on bone and mineral metabolism in the mouse. Calcified Tissue Int. 72, 32-41.
22. Sabokbar, A., O. Kudo, and N. A. Athanasou, 2003: Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J. Orthopaed. Res. 21, 73-80.
23. Sattler, A. M., M. Schoppet, J. R. Schäfer, and L. C. Hofbauer, 2004: Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcified Tissue Int. 74, 103-106.
24. Shaarawy, M., S. Zaki, M. Sheiba, and A. M. El Minawi, 2003: Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-β2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis. Clin. Lab. 49, 625-636.
25. Shinoda, K., E. Sugiyama, H. Taki, S. Harada, T. Mino, M. Maruyama, and M. Kobayashi, 2003: Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes. Bone 33, 711-720.
26. Sipos, W., C. Duvigneau, P. Pietschmann, K. Höller, R. Hartl, K. Wahl, R. Steinborn, M. Gemeiner, and F. Schmoll, 2003: Parameters of humoral and cellular immunity following vaccination of pigs with a European modified-life strain of porcine reproductive and respiratory syndrome virus (PRRSV). Viral Immunol. 16, 335-346.
27. Takayanagi, H., K. Ogasawara, S. Hida, T. Chiba, S. Murata, K. Sato, A. Takaoka, T. Yokochi, H. Oda, K. Tanaka, K. Nakamura, and T. Taniguchi, 2000: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408, 600-605.
28. Toraldo, G., C. Roggia, W. P. Qian, R. Pacifici, and M. N. Weitzmann, 2003: IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κ B ligand and tumor necrosis factor α from T cells. Proc. Natl. Acad. Sci. U.S.A. 100, 125-130.
29. Toussirot, E., and D. Wendling, 2004: The use of TNF-α blocking agents in rheumatoid arthritis: an overview. Exp. Opin. Pharmacother. 5, 581-594.
30. Troen, B. R., 2003: Molecular mechanisms underlying osteoclast formation and activation. Exp. Gerontol. 38, 605-614.
31. Yasuda, H., N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi, and T. Suda, 1998: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 95, 3597-3602.
32. Yoneda, T., N. Ishimaru, R. Arakaki, M. Kobayashi, T. Izawa, K. Moriyama, and Y. Hayashi, 2004: Estrogen deficiency accelerates murine autoimmune arthritis associated with RANKL-mediated osteoclastogenesis. Endocrinology 145, 2384-2391.